FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mikko Niemi

Research Profile

Concepts & Ideas

Procedures

Cross-Over Studies

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Single Nucleotide Polymorphism

Occupations

Pharmacogenetics

Co-author Network

Publications

TOP 3
Tuija Tapaninen; Janne T Backman; T Karonen; Pertti J Neuvonen; Mikko Niemi
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
E K Tarkiainen; Matthias Schwab; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Aleksi Tornio; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mikko Niemi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Tuija Tapaninen; Janne T Backman; T Karonen; Pertti J Neuvonen; Mikko Niemi
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Pharmacogenetics and genomics 2013;23(1):19-24.
2012: E K Tarkiainen; Matthias Schwab; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Clinical pharmacology and therapeutics 2012;92(1):68-71.
2012: Aleksi Tornio; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
Trends in pharmacological sciences 2012;33(6):312-22.
2012: J Honkalammi; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
Clinical pharmacology and therapeutics 2012;91(5):846-55.
2012: T Karonen; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
European journal of clinical pharmacology 2012;68(5):681-8.
2012: Xiaoqiang Xiang; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings.
Basic & clinical pharmacology & toxicology 2012;110(3):245-52.
2011: Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
European journal of clinical pharmacology 2011;67(11):1159-67.
2011: Tuija Tapaninen; Pertti J Neuvonen; Mikko Niemi
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.
British journal of clinical pharmacology 2011;71(5):718-26.
2011: J Honkalammi; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
Clinical pharmacology and therapeutics 2011;89(4):579-86.
2011: Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Pharmacological reviews 2011;63(1):157-81.
2011: Tuija Tapaninen; Janne T Backman; Kaisa J Kurkinen; Pertti J Neuvonen; Mikko Niemi
Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Journal of clinical pharmacology 2011;51(3):359-67.
2011: Alli Laitinen; Mikko Niemi
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Basic & clinical pharmacology & toxicology 2011;108(1):9-13.
2010: Annikka Kalliokoski; Pertti J Neuvonen; Mikko Niemi
SLCO1B1 polymorphism and oral antidiabetic drugs.
Basic & clinical pharmacology & toxicology 2010;107(4):775-81.
2010: T Tapaninen; Pertti J Neuvonen; Mikko Niemi
Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.
Clinical pharmacology and therapeutics 2010;88(3):339-42.
2010: Tuija Tapaninen; Pertti J Neuvonen; Mikko Niemi
Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
European journal of clinical pharmacology 2010;66(9):865-70.
2010: T Karonen; A Filppula; Jouko Laitila; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Clinical pharmacology and therapeutics 2010;88(2):223-30.
2010: Tuija Tapaninen; Pertti J Neuvonen; Mikko Niemi
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
European journal of clinical pharmacology 2010;66(5):497-502.
2010: Samuel Fanta; Siv Jönsson; Mats O Karlsson; Mikko Niemi; Christer Holmberg; Kalle Hoppu; Janne T Backman
Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.
Journal of clinical pharmacology 2010;50(5):581-97.
2010: Xiaoqiang Xiang; Yi Han; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi
High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(1):51-60.
2010: Mikko Niemi
Transporter pharmacogenetics and statin toxicity.
Clinical pharmacology and therapeutics 2010;87(1):130-3.
2009: Janne T Backman; Johanna Honkalammi; Mikko Neuvonen; Kaisa J Kurkinen; Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(12):2359-66.
2009: Jenni E Keskitalo; Marja K Pasanen; Pertti J Neuvonen; Mikko Niemi
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Pharmacogenomics 2009;10(10):1617-24.
2009: A Kalliokoski; Mikko Niemi
Impact of OATP transporters on pharmacokinetics.
British journal of pharmacology 2009;158(3):693-705.
2009: Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
British journal of clinical pharmacology 2009;68(2):207-13.
2009: J E Keskitalo; O Zolk; Martin F Fromm; K J Kurkinen; Pertti J Neuvonen; Mikko Niemi
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Clinical pharmacology and therapeutics 2009;86(2):197-203.
2009: Xiaoqiang Xiang; Yi Han; Mikko Neuvonen; Marja K Pasanen; Annikka Kalliokoski; Janne T Backman; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Pharmacogenetics and genomics 2009;19(6):447-57.
2008: Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
British journal of clinical pharmacology 2008;66(6):818-25.
2008: Annikka Kalliokoski; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Pharmacogenetics and genomics 2008;18(11):937-42.
2008: A Kalliokoski; Janne T Backman; K J Kurkinen; Pertti J Neuvonen; Mikko Niemi
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Clinical pharmacology and therapeutics 2008;84(4):488-96.
2008: J E Keskitalo; K J Kurkinen; P J Neuvoneni; Mikko Niemi
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Clinical pharmacology and therapeutics 2008;84(4):457-61.
2008: Marja K Pasanen; Tatu A Miettinen; Helena Gylling; Pertti J Neuvonen; Mikko Niemi
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pharmacogenetics and genomics 2008;18(10):921-6.
2008: Aleksi Tornio; Mikko Niemi; Mikko Neuvonen; Jouko Laitila; A Kalliokoski; Pertti J Neuvonen; Janne T Backman
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Clinical pharmacology and therapeutics 2008;84(3):403-11.
2008: Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Journal of clinical pharmacology 2008;48(3):311-21.
2008: Samuel Fanta; Mikko Niemi; Siv Jönsson; Mats O Karlsson; Christer Holmberg; Pertti J Neuvonen; Kalle Hoppu; Janne T Backman
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Pharmacogenetics and genomics 2008;18(2):77-90.
2008: Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Clinical pharmacokinetics 2008;47(7):463-74.
2008: Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):73-80.
2008: Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
British journal of clinical pharmacology 2008;65(1):78-86.
2007: Marja K Pasanen; Hanna Fredrikson; Pertti J Neuvonen; Mikko Niemi
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Clinical pharmacology and therapeutics 2007;82(6):726-33.
2007: Jari J Lilja; Mikko Niemi; Hanna Fredrikson; Pertti J Neuvonen
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.
British journal of clinical pharmacology 2007;63(6):732-40.
2007: Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
European journal of clinical pharmacology 2007;63(5):463-9.
2006: Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Clinical pharmacology and therapeutics 2006;80(6):565-81.
2006: Marja K Pasanen; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pharmacogenetics and genomics 2006;16(12):873-9.
2006: Mikko Niemi; Katja A Arnold; Janne T Backman; Marja K Pasanen; Ute Gödtel-Armbrust; Leszek Wojnowski; Uli Zanger; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö; Thomas Lang
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and genomics 2006;16(11):801-8.
2006: Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Clinical pharmacology and therapeutics 2006;80(4):356-66.
2006: Janne T Backman; Lauri I Kajosaari; Mikko Niemi; Pertti J Neuvonen
Cyclosporine A increases plasma concentrations and effects of repaglinide.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6(9):2221-2.
2006: Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Mikko Niemi; Pertti J Neuvonen
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
European journal of clinical pharmacology 2006;62(7):503-9.
2006: Mikko Niemi; Aleksi Tornio; Marja K Pasanen; Hanna Fredrikson; Pertti J Neuvonen; Janne T Backman
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
European journal of clinical pharmacology 2006;62(6):463-72.
2006: Marja K Pasanen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
European journal of clinical pharmacology 2006;62(6):409-15.
2006: Mia Hedman; Marjatta Antikainen; Christer Holmberg; Mikko Neuvonen; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen; Mikko Niemi
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
British journal of clinical pharmacology 2006;61(6):706-15.
2006: Michael Igel; Katja A Arnold; Mikko Niemi; ute hofmann; Matthias Schwab; Dieter Lütjohann; Klaus Von Bergmann; Michel Eichelbaum; Kari T Kivistö
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Clinical pharmacology and therapeutics 2006;79(5):419-26.
2006: Lauri I Kajosaari; Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Clinical pharmacology and therapeutics 2006;79(3):231-42.
2005: Lauri I Kajosaari; Mikko Niemi; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Cyclosporine markedly raises the plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2005;78(4):388-99.
2005: Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
British journal of clinical pharmacology 2005;60(2):208-17.
2005: Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B S Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Clinical pharmacology and therapeutics 2005;77(6):468-78.
2004: Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Clinical pharmacology and therapeutics 2004;76(3):239-49.
2004: Mikko Niemi; Lauri I Kajosaari; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
British journal of clinical pharmacology 2004;57(4):441-7.
2004: Jari J Lilja; Mikko Niemi; Pertti J Neuvonen
Rifampicin reduces plasma concentrations of celiprolol.
European journal of clinical pharmacology 2004;59(11):819-24.
2003: Mikko Niemi; Julian B S Leathart; Mikko Neuvonen; Janne T Backman; Ann K Daly; Pertti J Neuvonen
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2003;74(4):380-7.
2003: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
British journal of clinical pharmacology 2003;56(4):427-32.
2003: Mikko Niemi; Janne T Backman; Marika T Granfors; Jouko Laitila; Mikko Neuvonen; Pertti J Neuvonen
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Diabetologia 2003;46(10):1319-23.
2003: Mikko Niemi; Mikko Neuvonen; Laura Juntti-Patinen; Janne T Backman; Pertti J Neuvonen
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Clinical pharmacology and therapeutics 2003;74(1):25-31.
2003: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Diabetologia 2003;46(3):347-51.
2003: Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Pharmacokinetic interactions with rifampicin : clinical relevance.
Clinical pharmacokinetics 2003;42(9):819-50.
2002: Kari Raaska; Mikko Niemi; Mikko Neuvonen; Pertti J Neuvonen; Kari T Kivistö
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
Clinical pharmacology and therapeutics 2002;72(4):362-9.
2002: Mikko Niemi; Ingolf Cascorbi; Ramona Timm; Heyo K Kroemer; Pertti J Neuvonen; Kari T Kivistö
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Clinical pharmacology and therapeutics 2002;72(3):326-32.
2001: Mikko Niemi; Pertti J Neuvonen; Kari T Kivistö
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;70(5):439-45.
2001: Mikko Niemi; Pertti J Neuvonen; Kari T Kivistö
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2001;70(1):58-65.
2001: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Kari T Kivistö
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
Clinical pharmacology and therapeutics 2001;69(6):400-6.
2001: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Kari T Kivistö
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;69(4):194-200.
2000: Mikko Niemi; Kari T Kivistö; Janne T Backman; Pertti J Neuvonen
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
British journal of clinical pharmacology 2000;50(6):591-5.
2000: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Kari T Kivistö
Rifampin decreases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2000;68(5):495-500.
2000: T Kantola; Janne T Backman; Mikko Niemi; Kari T Kivistö; Pertti J Neuvonen
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
European journal of clinical pharmacology 2000;56(3):225-9.